Loading stock data…
EYPT
$13.34+0.14 (+1.06%)
Market ClosedLast close May 1
EyePoint, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
EyePoint, Inc. in the Healthcare sector is trading at $13.34. The stock is currently 30% below its 52-week high of $19.11, remaining 3.1% below its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why EYPT maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 35) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.34
Potential Upside
5%
Whystock Fair Value$14.01
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$37.17+178.6%
Range$20.00 – $68.00
Fundamentals
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug de...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.91
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-57.29%
Volume
Today's trading volume
904,999
Recent News
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference
Executives from Eyepoint Pharmaceuticals (NASDAQ:EYPT) told investors at RBC Capital Markets’ Ophthalmology Conference that the company’s lead program, DURAVYU (vorolanib), is advancing through four Phase 3 studies in retinal disease, with the first top-line readout expected around August. Lead pro
How The EyePoint (EYPT) Story Is Shifting With Phase 3 DME And Duravyu In Focus
Analysts covering EyePoint have refreshed their models, with bullish price targets now clustered in the US$29 to US$35 range. These revisions are being linked to more detailed valuation work on the late stage pipeline, especially the Phase 3 diabetic macular edema program, and ongoing tracking of Duravyu execution after the Q4 report. As you read on, you will see how these moving pieces shape the evolving story and what to watch to stay on top of the narrative. Stay updated as the Fair Value...
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
March 20 () - EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug. The complaint was filed in Middlesex County Superior Court for the Commonwealth of Massachusetts.
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.